Sbir proposal for PHS 2009-1 topic 266 for a targeted nanocomplix for early detection of lung cancer

Ended Definitive Contract Awarded Last action

Contract number
HHSN261200900046C
Awardee
Awarding agency
Obligated
$1,196,639

Award facts

Opportunity
Contract value 100% obligated
$1,196,639.40 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541711 Research and Development in Biotechnology
PSC
AN11 Health R&D Services; Health Care Services; Basic Research
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 19 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Potomac, MD 20854, USA
Research
SBIR Program Phase I Action

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out 5 · Amended to deobligate uninvoiced funds that remained in the contract after contract closure. -$1
Other Administrative Action 4 · Amended to administratively change the centeral point of distribution to NCI INV-BR-C $0
Exercise an Option 3 $498,331
Exercise an Option 2 · Synergene, INC sbir phase II option period $498,331
Other Administrative Action 1 $0
Original award $199,978

Quick answers

Who was awarded contract HHSN261200900046C?

HHSN261200900046C was awarded to Synergene Therapeutics Inc. by National Cancer Institute (National Institutes of Health) on September 30, 2009.

How much is contract HHSN261200900046C worth?

The government has obligated $1,196,639 on HHSN261200900046C.

Was contract HHSN261200900046C competed?

The extent of competition for HHSN261200900046C was full and open competition after exclusion of sources. The government received 19 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login